Clinical Trial

A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

Name: A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China. — clinical trial record (NCT07647224)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.

Trial Details

NCT Number	NCT07647224
Lead Sponsor	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions	Multiple Dose, Healthy Adult Participants
Enrollment	36 participants
Start Date	2026-06
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-15